Pharma giant Merck is stopping a key Alzheimer's trial because...

Pharma giant Merck is stopping a key Alzheimer's trial because...


Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness. Merck said the external data monitoring committee, which assessed overall benefit or risk of verubecestat, determined that there was "virtually no chance of finding a positive clinical effect".



from Biotech News